SUBSEQUENT EVENTS - Additional Information (Detail) - Subsequent Event - Novartis - Collaboration And License Agreement - USD ($) $ in Millions		1 Months Ended
	Jul. 27, 2020	Aug. 27, 2020
Subsequent Event [Line Items]
Period of collaboration	3 years
Extended period of collaboration	2 years
Forecast
Subsequent Event [Line Items]
Proceeds from collaborators		$ 75.0
Maximum | Achievement of Specified Preclinical Development Clinical Development and First Commercial Sale Milestones
Subsequent Event [Line Items]
Development and sales-based milestone payments to be received	$ 420.0
Maximum | Achievement of Commercial Milestones
Subsequent Event [Line Items]
Development and sales-based milestone payments to be received	$ 300.0